孕激素单药避孕与WHO I级脑膜瘤绝经前女性更短的无进展生存期相关
比较67例接受手术切除的WHO I级颅内脑膜瘤绝经前女性,其中孕激素单药避孕21例、雌激素单药或雌孕激素联合避孕46例。孕激素单药组复发率更高(33.3% vs 19.6%),复发时间更短(18 vs 32个月,p=0.038),尽管随访时间显著更短(p=0.014)。作者认为孕激素单药避孕可能是脑膜瘤患者应避免的避孕亚组。
要点
- 孕激素单药避孕组复发率33.3%,雌激素单药或雌孕激素联合组19.6%。
- 孕激素单药组复发时间18个月,对照组32个月,p=0.038。
- 孕激素单药组随访时间显著更短,p=0.014。
核心结论
- 孕激素单药避孕可能增加WHO I级脑膜瘤术后复发并缩短无进展生存期,作者认为该类避孕药可能是脑膜瘤患者应避免的特定亚组。
研究设计与样本
- 对67例接受手术切除的WHO I级颅内脑膜瘤绝经前女性进行对比分析,其中孕激素单药避孕21例,雌激素单药或雌孕激素联合避孕46例。
主要发现
- 孕激素单药避孕组复发率33.3%,雌激素单药或雌孕激素联合组19.6%。
- 孕激素单药避孕组复发时间18个月,对照组32个月,p=0.038。
- 孕激素单药避孕组随访时间显著短于对照组,p=0.014。
- 两组在人口学特征、切除程度及辅助治疗方面无显著差异。
临床怎么用
- 作者认为孕激素单药避孕可能是脑膜瘤患者应避免的特定避孕亚组。
局限性
- 孕激素单药避孕组随访时间显著短于对照组,p=0.014。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The hormonally active nature of intracranial meningioma has prompted research examining the risk of tumorigenesis in patients using hormonal contraception. Studies exploring estrogen-only and estrogen/progesterone combination contraceptives have failed to demonstrate a consistent increased risk of meningioma. By contrast, the few trials examining progesterone-only contraceptives have shown higher odds ratios for risk of meningioma. With progesterone-only contraception on the rise, the risk of tumor recurrence with these specific medications warrants closer study. We sought to determine whether progesterone-only contraception increases recurrence rate and decreases progression-free survival in pre-menopausal women with surgically resected WHO Grade I meningioma. Comparative analysis of 67 pre-menopausal women taking hormone-based contraceptives (progesterone-only medication, n = 21; estrogen-only or estrogen/progesterone combination medication, n = 46) who underwent surgical resection of WHO Grade I intracranial meningioma was performed. Differences in demographics, degree of resection, adjuvant therapy and time to recurrence were compared between the two groups. Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a reduced time to recurrence (18 vs. 32 months, p = 0.038) despite a significantly shorter follow-up (p = 0.014). There were no significant demographic or treatment related differences. The results from this study suggest that exogenous progesterone-only medications may represent a specific contraceptive subgroup that should be avoided in patients with meningioma.
引用
- Harland TA, Freeman JL, Davern M, et al. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol. 2017. PMID: 29081037. doi:10.1007/s11060-017-2656-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。